GlassScriptPhysician profile
Lanway H Ling
NPI 1932173598
$8,584.00
in general payments reported to CMS, 2019-2025
48 companies · $990 in 2025
The $990 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,175 · 2020: $1,240 · 2021: $1,257 · 2022: $1,405 · 2023: $1,275 · 2024: $1,243 · 2025: $990.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,507.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,507.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,214.40 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $845.50 | 2019-2025 | |
| Glaxosmithkline, LLC. | $830.05 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $664.65 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $555.48 | 2019-2025 | |
| Lilly USA, LLC | $391.22 | 2019-2025 | Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $387.07 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $353.14 | 2019-2023 | |
| Lundbeck LLC | $238.99 | 2022-2025 | Rexulti |
| Exact Sciences Corporation | $227.12 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $206.97 | 2019-2025 | Trintellix |
| Merck Sharp & Dohme LLC | $192.98 | 2019-2023 | Belsomra |
| Axsome Therapeutics, INC. | $181.23 | 2023-2025 | Sunosi, Auvelity |
| Astellas Pharma US INC | $160.18 | 2019-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $156.51 | 2024-2025 | Rexulti |
Show all 47 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lanway Ling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.